Provider: Excerpta Medica

Company Profile
Excerpta Medica Inc., an Elsevier business, is a global medical communications company headquartered in the US and The Netherlands. Since 1946, Excerpta Medica (www.excerptamedica.com) has been partnering with its clients in the pharmaceutical and biotech industries to ensure healthcare professionals will have the information they need to make informed decisions regarding treatment options for their patients. As part of Elsevier, the world's largest medical and scientific publisher,Excerpta Medica leverages Elsevier's many resources to build unique and powerful medical communications solutions.

Services and Offerings
The team of professionals at Excerpta Medica creates and delivers a full line of strategic solutions in the areas of:

Publication Planning:
Excerpta Medical develops and implements publication plans, produces abstracts and posters for scientific congresses, and performs gap and competitor analyses.

Medical Education:
We deliver a range of strategic, scientific and creative communication solutions including symposia, teleconferences, advisory board and investigator meetings, slide kits and e-media.

Custom and Medical Publishing:
We offer a variety of publication solutions ranging from peer-reviewed titles and industry-sponsored publications to customized communication solutions based on clien and target audience needs.

Interactive Solutions:
Our award-winning team at Excerpta Medica Interactive creates and implements innovative online medical communications solutions that successfully drive clients' educational strategies. We achieve our clients' goals by creating innovative, intuitive and interactive solutions for the world's leading healthcare brands.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.